CPHI Barcelona 2023: Our Expert Leads the Way to the Future of Generics

Dr. Ayaaz Hussain Khan, Global Head of Generics at Navitas Life Sciences, will be a distinguished presence at CPHI 2023. With a wealth of experience and vast expertise, Dr. Khan will be present to find solutions for your unique needs and to provide a glimpse into the future of generics.

In this blog, we spoke to Dr. Khan, to ask what CPHI North Barcelona means to life sciences, biotech and pharma professionals across the world.

What does it signify for Navitas Life Sciences to have a presence at CPHI Barcelona 2023?

It's a great opportunity for us to establish new connections. Navitas Life Sciences is committed to transforming patients’ lives by managing efficient clinical trials and bringing drug products to the market faster.

CPHI Barcelona will aid in maintaining a close connection with our sponsors on an annual basis, understanding their needs, and exploring how we can enhance our services. Being physically present at this event allows us to forge meaningful relationships and offer tailored solutions to our valued partners.

How are regional events like CPHI Barcelona 2023 crucial aid the pharmaceutical services industry in Europe?

Regional events like CPHI Barcelona 2023 play a pivotal role, particularly for the pharma services industry in Europe. They serve as a vital platform for engaging with our clients based in this region. Europe, with its dynamic market, is teeming with potential partners involved in innovative pharmaceutical products. Additionally, considering the economic constraints and the evolving travel landscape, regional events offer a cost-effective option for smaller enterprises, allowing them to participate and benefit from this invaluable networking opportunity.

Tell us about the new exclusive facility for BA/BE studies.

Our new Bioavailability/Bioequivalence (BA/BE) facility is a wonderful addition to our capabilities and infrastructure. Spanning an impressive 32,000 square feet across four floors, it's designed to facilitate a wide range of studies with utmost precision and efficiency.

The facility has a Clinical Pharmacology Unit with a capacity of 150 beds, ensuring ample space for rigorous clinical trials. Additionally, we've incorporated a dedicated screening area to streamline participant selection, providing a conducive environment for accurate assessments. One of the key highlights is our Integrated Clinical Testing Facility, which is equipped to handle a variety of studies, from pharmacokinetics to biomarker evaluations. We've taken special care to include multiple wards to accommodate mixed-gender studies, ensuring a diverse participant pool for comprehensive research outcomes.

For studies focused on insulin sensitivity and related research, our state-of-the-art Euglycemic Clamp Facility is at the forefront of scientific advancement. Finally, the Bioanalytical Laboratory sets a new standard in analytical precision. With advanced technology and a stringent quality framework, it's poised to deliver reliable and insightful data, essential for informed decision-making in drug development.

In essence, our new BA/BE facility represents a significant leap forward in advancing pharmaceutical research and underscores Navitas Life Sciences' dedication to excellence in conducting state-of-the-art BA/BE studies.

Please describe your inspections by regulatory authorities

Navitas Life Sciences has a flawless track record with regulatory authorities, achieving successful inspections with zero observations. This unwavering commitment to compliance ensures that every project is executed with the highest standards of quality and safety.

Recently, WHO conducted an inspection of our new BA/BE facility, and it was successful with no critical observations.

What is our expertise in managing Complex Studies?

We specialize in executing scientifically challenging studies, including NCE-1, FTF, multi-drug combination Inhalation studies, euglycemic clamp studies, PK/PD endpoint studies, Liposomal studies, immunogenicity studies and more. Our dedication to ensuring compliance and cost and time efficiency sets Navitas Life Sciences apart as a preferred partner for complex studies.

Tell us more about the Euglycemic Clamp Studies

Experience the gold standard in measuring insulin action on glucose utilization with Navitas Life Sciences. Through state-of-the-art Euglycemic clamp studies, we measure the glucose-lowering effect of biosimilar insulin compounds, employing variable glucose infusion rates. This innovative approach promises groundbreaking advancements in diabetes care.

We ensure that your biosimilar study is conducted with the highest level of compliance with regulatory requirements. We have invested in and built up the necessary expertise and infrastructure to ensure that your biosimilar Insulin product is launched quickly. With our extensive experience, we understand and have mastered the challenges of deploying the appropriate study design to effectively and scientifically demonstrate the biosimilarity of your product.

How do you ensure that Iron carbohydrate complex formulations are swift to market?

Navitas Life Sciences has honed methodologies for evaluating Iron-Carbohydrate preparations like iron sucrose and ferric carboxy maltose, ensuring a streamlined path to market for complex injectable iron formulations.

In your Inhalation Studies, how do you ensure targeted treatment and higher efficiency?

Inhalation studies offer a game-changing advantage in drug delivery. The clinical execution of inhalation studies has taken a higher level of sophistication with several individual negative pressure chambers for dosing to prevent cross spreading of the drug in the dosing area and among other volunteers. We have extensive expertise in MDI, DPI, Nasal Spray & Charcoal Administration.

What are your capabilities for ligand binding assay?

Navitas Life Sciences prides itself on a comprehensive set of capabilities. We possess expertise in developing, validating, and executing a wide range of ligand binding assays, catering to diverse needs.

Our state-of-the-art technologies and adherence to stringent quality standards ensure accurate and reliable results. With a wealth of experience, our scientists are adept at customizing assays to meet specific project requirements. Whether it's for pharmacokinetic, biomarker, or immunogenicity assessments, our capabilities in ligand binding assays are designed to provide robust and insightful data for informed decision-making in drug development.

What are the facilities available in the Bioanalytical Labs?

Navitas Life Sciences' GLP compliant Bioanalytical labs are equipped with 21CFR part 11 compliant LC-MS/MS and ICPMS systems, providing a state-of-the-art environment for precision research. With a library of over 450 validated assays, including highly sensitive methods for key compounds, Navitas Life Sciences stands at the forefront of analytical excellence.

Leverage our 450+ validated Bioanalytical Methods Capability

Utilize our extensive catalog of over 450 Validated Bioanalytical Techniques for your research. Our team can create and validate a method tailored to your needs within a four-week timeframe.

Access the List Now

With all these capabilities and infrastructure support, Navitas Life Sciences is poised to revolutionize the generics industry. Join us at CPHI 2023 and be part of the future of pharmaceutical innovation.

CPHI Barcelona 2023

Date: 24 - 26 October 2023

Venue: Fira Barcelona Gran Via, Spain

Navitas Life Sciences are pleased to be attending the upcoming CPHI event in Barcelona.

Schedule a Meeting Now

Meet our Expert

Dr Ayaaz Hussain Khan

Global Head of Generics

To know more about our services and solutions, reach out to us at This email address is being protected from spambots. You need JavaScript enabled to view it.